Andrius Žučenka: The results of our novel 4-drug regimen G-ACTIVE for FLT3 mutated relapsed/refractory acute myeloid leukemia

Andrius Žučenka, Hematologist, Researcher, Lecturer and PhD Candidate at Vilnius University Hospital Santaros Klinikos, made the following post on LinkedIn:

“Our recent paper on combined targeted therapy for FLT3 mutated relapsed/refractory acute myeloid leukemia has just been published!

In this report we demonstrate the results of our novel 4-drug regimen G-ACTIVE, consisting of the FLT3 inhibitor Gilteritinib, BCL-2 inhibitor Venetoclax, and two low-dose chemotherapy agents (Cytarabine and Actinomycin D). Our treatment resulted in a 95% overall response rate, a median overall survival of 32 months and allowed the majority of patients to proceed to curative allogeneic stem cell transplantation.

For more details/manuscript please contact me.”

Read further.
Source: Andrius Žučenka/LinkedIn